Changes in diabetes prescription patterns following Affordable Care Act Medicaid expansion

Jordan Gemelas, Miguel Marino, Steele Valenzuela, Teresa Schmidt, Andrew Suchocki, Nathalie Huguet, Jordan Gemelas, Miguel Marino, Steele Valenzuela, Teresa Schmidt, Andrew Suchocki, Nathalie Huguet

Abstract

Introduction: Most patients with diabetes mellitus are prescribed medications to control their blood glucose. The implementation of the Affordable Care Act (ACA) led to improved access to healthcare for patients with diabetes. However, impact of the ACA on prescribing trends by diabetes drug category is less clear. This study aims to assess if long-acting insulin and novel agents were prescribed more frequently following the ACA in states that expanded Medicaid compared with non-expansion states.

Research design and methods: In this analysis of a natural experiment, prescriptions reimbursed by Medicaid (US public insurance) for long-acting insulins, metformin, and novel agent medications (DPP4 inhibitors, sodium/glucose cotransporter 2 inhibitor antagonists, and glucagon-like peptide-1 receptor agonists) from 2012 to 2017 were obtained from public records. For each medication category, we performed difference-in-differences (DID) analysis modeling change in rate level from pre-ACA to post-ACA in Medicaid expansion states relative to Medicaid non-expansion states.

Results: Expansion and non-expansion states saw a decline in both metformin and long-acting insulin prescriptions per 100 enrollees from pre-ACA to post-ACA. These decreases were larger in non-expansion states relative to expansion states (metformin: absolute DID = +0.33, 95% CI=0.323 to 0.344) and long-acting insulin (absolute DID: +0.11; 95% CI=0.098 to 0.113). Novel agent prescriptions in expansion states (+0.08 per 100 enrollees) saw a higher absolute increase per 100 Medicaid enrollees than in non-expansion states (absolute DID= +0.08, 95% CI=0.079 to 0.086).

Conclusions: There was a greater absolute increase for prescriptions of novel agents in expansion states relative to non-expansion states after accounting for number of enrollees. Reducing administrative barriers and improving the ability of providers to prescribe such newer therapies will be critical for caring for patients with diabetes-particularly in Medicaid non-expansion states.

Keywords: drug utilization; health policy; primary health care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Unadjusted Medicaid expansion and non-expansion state yearly trends in (A) metformin, (B) long-acting insulin, and (C) novel agent prescription rates from 2012 to 2017.

References

    1. US Department of Health and Human Services . United States centers for disease control and prevention. National diabetes statistics report, 2020. Available:
    1. Rodbard HW, Green AJ, Fox KM, et al. . Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses. Diabetes Res Clin Pract 2010;87:360–5. 10.1016/j.diabres.2009.11.021
    1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. 10.1056/NEJM199309303291401
    1. Garber AJ, Handelsman Y, Grunberger G, et al. . Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract 2020;26:107–39. 10.4158/CS-2019-0472
    1. Svanström H, Ueda P, Melbye M, et al. . Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol 2019;7:106–14. 10.1016/S2213-8587(18)30320-6
    1. Pasternak B, Wintzell V, Eliasson B, et al. . Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 2020;43:1326–35. 10.2337/dc19-2088
    1. Cefalu WT, Dawes DE, Gavlak G, et al. . Insulin access and affordability Working group: conclusions and recommendations. Diabetes Care 2018;41:1299–311. 10.2337/dci18-0019
    1. Grant RW, Wexler DJ, Watson AJ, et al. . How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 2007;30:1448–53. 10.2337/dc06-2499
    1. Kaiser Family Foundation . Status of state medicaid expansion decisions: interactive map [Internet]. KFF, 2020. Available:
    1. Tolbert J, Orgera K, Singer N. Key facts about the uninsured [Internet]. Henry J Kaiser Family Foundation, 2019. Available:
    1. Myerson R, Romley J, Chiou T, et al. . The Affordable care act and health insurance coverage among people with diagnosed and undiagnosed diabetes: data from the National health and nutrition examination survey. Diabetes Care 2019;42:e179–80. 10.2337/dc19-0081
    1. Kaufman HW, Chen Z, Fonseca VA, et al. . Surge in newly identified diabetes among Medicaid patients in 2014 within Medicaid expansion states under the Affordable care act. Diabetes Care 2015;38:833–7. 10.2337/dc14-2334
    1. Angier H, Huguet N, Ezekiel-Herrera D, et al. . New hypertension and diabetes diagnoses following the Affordable care act Medicaid expansion. Fam Med Community Health 2020;8:e000607. 10.1136/fmch-2020-000607
    1. Chen EM, Armstrong GW, Cox JT, et al. . Association of the Affordable care act Medicaid expansion with dilated eye examinations among the United States population with diabetes. Ophthalmology 2020;127:920–8. 10.1016/j.ophtha.2019.09.010
    1. Marino M, Angier H, Fankhauser K, et al. . Disparities in biomarkers for patients with diabetes after the Affordable care act. Med Care 2020;58 Suppl 6 Suppl 1:S31–9. 10.1097/MLR.0000000000001257
    1. Casagrande SS, McEwen LN, Herman WH. Changes in health insurance coverage under the Affordable care act: a national sample of U.S. adults with diabetes, 2009 and 2016. Diabetes Care 2018;41:956–62. 10.2337/dc17-2524
    1. Lindner SR, Marino M, O’Malley J, et al. . Health care expenditures among adults with diabetes after oregon’s medicaid expansion. Diabetes Care 2020;43:572–9. 10.2337/dc19-1343
    1. Ghosh A, Simon K, Sommers BD. The Effect of Health Insurance on Prescription Drug Use Among Low-Income Adults:Evidence from Recent Medicaid Expansions. J Health Econ 2019;63:64–80. 10.1016/j.jhealeco.2018.11.002
    1. Myerson R, Lu T, Tonnu-Mihara I, et al. . Medicaid eligibility expansions may address gaps in access to diabetes medications. Health Aff 2018;37:1200–7. 10.1377/hlthaff.2018.0154
    1. Hill SC, Abdus S, Hudson JL, et al. . Adults in the income range for the Affordable care act's Medicaid expansion are healthier than pre-ACA enrollees. Health Aff 2014;33:691–9. 10.1377/hlthaff.2013.0743
    1. Vistnes JP, Lipton B, Miller GE. Uninsurance and insurance transitions before and after 2014: estimates for U.S., Non-elderly adults by health status, presence of chronic conditions and state medicaid expansion status. 2016 Jun. In: statistical brief (medical expenditure panel survey (US)) [Internet]; STATISTICAL BRIEF #490. Rockville (MD: Agency for Healthcare Research and Quality (US), 2001.
    1. Guerci B, Chanan N, Kaur S, et al. . Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther 2019;10:437–49. 10.1007/s13300-019-0590-x
    1. Giorgino F, Penfornis A, Pechtner V, et al. . Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Prefer Adherence 2018;12:707–19. Volume. 10.2147/PPA.S151736
    1. Walker RJ, Gebregziabher M, Martin-Harris B, et al. . Independent effects of socioeconomic and psychological social determinants of health on self-care and outcomes in type 2 diabetes. Gen Hosp Psychiatry 2014;36:662–8. 10.1016/j.genhosppsych.2014.06.011
    1. Medicaid . State drug utilization data | Medicaid, 2020. Available:
    1. Meiri A, Zhang F, Ross-Degnan D, et al. . Trends in insulin out-of-pocket costs and reimbursement price among US patients with private health insurance, 2006-2017. JAMA Intern Med 2020;180:1010. 10.1001/jamainternmed.2020.1302
    1. Kaiser Family Foundation . Current Medicaid and CHIP enrollment, 2020. Available:
    1. America’s Health Rankings, United Health Foundation . Analysis of CDC, behavioral risk factor surveillance system, 2012-2017. Available:
    1. U.S. Department of Labor, Bureau of Labor Statistics . Local area unemployment statistics. 2012-2017. Available:
    1. American Diabetes Association . 6. glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43:S66–76. 10.2337/dc20-S006
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669–701. 10.2337/dci18-0033
    1. Ham SA, Nathan A, Laiteerapong N, et al. . Cost-Related barriers to new diabetes Medications—A national physician survey. Diabetes 2018;67:149-LB–LB. 10.2337/db18-149-LB

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner